MedTrace Logo

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

NCT05709626 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2258

Last updated 2023-03-01

No results posted yet for this study

Summary

The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).

Conditions

  • ST-segment Elevation Myocardial Infarction (STEMI)

Interventions

DRUG

No aspirin (Prasugurel monotherapy)

12-month prasugrel monotherapy

DRUG

12-month DAPT

12-month dual antiplatelet therapy with prasugrel and aspirin

Sponsors & Collaborators

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Kindai University

    lead OTHER

Principal Investigators

  • Gaku Nakazawa, MD, PhD · Kindai University Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2025-01-04
Completion
2028-01-04

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05709626 on ClinicalTrials.gov